Oric Pharmaceuticals, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Oric Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2019 to Q3 2024.
  • Oric Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$34.6M, a 35.7% decline year-over-year.
  • Oric Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$120M, a 28.6% decline year-over-year.
  • Oric Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$101M, a 13% decline from 2022.
  • Oric Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$89.1M, a 13.2% decline from 2021.
  • Oric Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$78.7M, a 6.8% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$120M -$34.6M -$9.09M -35.7% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 -$111M -$32M -$9.02M -39.3% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-12
Q1 2024 -$102M -$25M -$1.07M -4.45% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-06
Q4 2023 -$101M -$28.3M -$7.48M -35.9% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-11
Q3 2023 -$93.2M -$25.5M -$649K -2.61% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$92.6M -$22.9M -$2.66M -13.1% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-12
Q1 2023 -$89.9M -$23.9M -$786K -3.39% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-06
Q4 2022 -$89.1M -$20.8M +$1.92M +8.45% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-11
Q3 2022 -$91M -$24.8M -$6.4M -34.8% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-06
Q2 2022 -$84.6M -$20.3M +$722K +3.44% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$85.4M -$23.2M -$6.65M -40.3% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 -$78.7M -$22.8M +$5.49M +19.4% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-16
Q3 2021 -$84.2M -$18.4M +$7.12M +27.9% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 -$91.3M -$21M -$9.99M -90.6% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 -$81.3M -$16.5M -$7.64M -86.1% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 -$73.7M -$28.3M -$19.9M -238% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-21
Q3 2020 -$53.8M -$25.5M -$19M -290% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 -$34.8M -$11M -$5.06M -84.8% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-10
Q1 2020 -$29.7M -$8.87M -$2.86M -47.5% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$26.9M -$8.35M Oct 1, 2019 Dec 31, 2019 10-K 2022-03-21
Q3 2019 -$6.55M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$5.97M Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 -$6.02M Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-20
* An asterisk sign (*) next to the value indicates that the value is likely invalid.